期刊文献+

缓控释非胃肠道给药系统的体外加速释放方法综述 被引量:1

A Summary of in vitro Accelerated Approaches for Controlled Release Parenteral Drug Delivery System
原文传递
导出
摘要 近年来,长效缓控释非胃肠道给药系统由于具有减少给药频率、提高药效、降低药物副作用和增加患者的顺应性等传统给药系统不能比拟的优势,在科学研究和临床应用中引起广泛关注和应用。对于缓控释非胃肠道给药系统的研发生产和质量控制来说,监测其体外的实时释放需要耗费数周乃至数月的时间,因此建立适当的体外加速释药方法是保证其质量、特性以及各批次间稳定性的关键步骤。文章对缓控释非胃肠道给药系统的体外加速释放的不同方法,如温度、pH值、添加有机溶剂或表面活性剂等进行了综述。 In recent years,long-term controlled release parenteral drug delivery system has attracted considerable attention in clinical and research fields because of its advantages compared with traditional drug delivery systems,including reducing dosing frequency,increasing drug efficacy,decreasing adverse side effects,and enhancing patient compliance.In the process of product development and quality control,real-time in vitro release tests for these dosage forms are often run over periods of weeks and months which are time consuming.Hence,the establishment of appropriate accelerated in vitro release methods is the key step to guarantee the quality,features and stability of each batch.In this paper,various of methods related to acceleration in vitro release studies include temperature,pH value,addictive of organic solvent or surfactant etc.are reviewed.
作者 林艳 LIN Yan(Department of Pharmacy,YangPu Affiliated Hospital,Tongji University&Shanghai Yangpu District Central Hospital,Shanghai 200090,China)
出处 《药物生物技术》 CAS 2019年第2期182-185,共4页 Pharmaceutical Biotechnology
关键词 体外加速释放实验 缓控释非胃肠道给药系统 质量控制 体内-体外相关性 PH值 释药机制 Accelerated in vitro release testing Controlled release parenteral drug delivery system Quality control in vivo-in vitro correlation pH value Release mechanism
  • 相关文献

参考文献2

二级参考文献63

  • 1陈庆华,陈刚,唐海芸.利培酮长效注射剂的药动学特征和临床应用[J].中国新药杂志,2006,15(15):1235-1238. 被引量:8
  • 2CONGRONG L, GANGADHAR S, JOHN BC, et al. Recent ad- vances in prodrugs as drug delivery systems[ J]. Amer J Therap, 2012, 19(1): 33 -43.
  • 3Invega Sustanna Full Prescribing Information[ EB/OL]. [2009 - 05 - 10]. http://www, fda. gov.
  • 4Depo-Testosterone Package Insert: Pharmcia and Upjohn Com- pany [ EB/OL]. [ 2002 - 03 - 04 ]. http ://www. fda. gov.
  • 5ABUCHOWSKI A, VANES T, PALCZUK NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[ J]. J Biol Chem, 1977, 252 (1): 3578 -3581.
  • 6INADA Y, FURUKAWA M, SASAKI H, et al. Biomedical and biotechnological applications of PEG- and PM- modified proteins [J]. Trends Biotechnol, 1995, 13(3): 86 -91.
  • 7WANG YS, YONGSTER S, GRACE M, et al. Structural and bi- ological characterization of pegylated recombinant interferon al- pha-2b and its therapeutic application[ J]. Adv Drug Deliv Rev, 2002, 54(4) : 547 -570.
  • 8REDDY KR, MODI M W, PEDDER S. Use of peginterferon al- fa-2a (40KD) ( Pegasys ) for the treatment of hepatitis C[ J]. Adv Drug Deliv Rev, 2002, 54(4) : 571 -584.
  • 9ALCONCEL SN, BAAS AS, Maynard HD. FDA-approved poly ( ethylene glycol )-protein conjugate drugs [ J ]. Polym Chem, 2011, 2(7) : 1442 -1448.
  • 10DINNDROF PA, GOOTENBER J, COHEN MH, et al. FDA drug approval summary : pegaspargase ( Oncaspar ) for the first- line treatment of children with acute lymphoblastic leukemia (ALL)[J]. Oncologist, 2007, 12(8): 991 -998.

共引文献12

同被引文献17

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部